abstract |
The invention provides anti-influenza modified oligonucleotides that have greater efficacy in inhibiting influenza replication or propagation than previously described oligonucleotides. The greater efficacy arises from structural features such as chimeric or hybrid backbones, nuclease resistance-conferring terminal capping structures and/or self-complementary regions. |